Arena conducted three-month rat studies that relied on biomarkers of mammary tumor growth to prove its case. The FDA asked Arena to conduct 12-month rat studies, which would provide more definitive proof. When is it a good idea to ignore the FDA's recommendations?
If you want to better understand FDA concerns about the role lorcaserin may play in tumor growth, you can check out the agency's presentation from Arena's advisory panel in September 2010. In particular, look at slide 17, which shows how d-fenfluramine raised prolactin levels in rats more than lorcaserin. [D-fenfluramine and lorcaserin are similar drugs.] However, as the FDA points outs, d-fenfluramine did not produce mammary tumors in two-year rat studies.
This suggests lorcaserin may be causing mammary tumors in rats through some mechanism other than by raising prolactin levels. That's why FDA asked Arena to run longer animal studies. Without those data, I don't see how the FDA is going to be confident enough in lorcaserin's safety to approve.
Outside of the rat tumor issue, lorcaserin may also cause heart valve defects, according to data from a follow-on study of the drug when to treat obesity in diabetics. The FDA will be reviewing these data from the diabetes study for the first time since they were not included in Arena's original submission. The cardiovascular risk of lorcaserin is probably a bigger problem than rat tumors, but it's something the company and its supporters tend to brush under the rug.The FDA approves drugs when the benefits outweigh the risks. We already know that the FDA considers lorcaserin's weight-loss benefit to be "marginal" yet the safety risks are significant. For Arena, that's not a winning formula. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV